輸血基準値と出血リスク（RCTメタ解析、森林プロット）中等度以上の出血エピソード発生イベント数の比較

出典
imgimg
1: Platelet transfusions for patients with haematological malignancies: who needs them?
著者: Estcourt LJ, Stanworth SJ, Murphy MF.
雑誌名: Br J Haematol. 2011 Aug;154(4):425-40. doi: 10.1111/j.1365-2141.2010.08483.x. Epub 2011 May 25.
Abstract/Text: The goal of platelet transfusions is to prevent severe and life-threatening bleeding in patients with thrombocytopenia. This aim needs to be balanced against the risks associated with platelet transfusions as well as the challenge of maintaining an adequate supply. This review summarizes the recent evidence regarding the clinical use of platelet transfusions in haematology patients, concentrating on the topics that still continue to provoke debate. These include the optimal dose for platelet transfusions and the relative safety of a 'therapeutic only' platelet transfusion strategy compared to the use of prophylactic platelet transfusions. The type of platelet product has been the subject of two recent systematic reviews. The results of these reviews will be discussed as well as their implications for current practice.

Published with the permission of the Controller of HMSO and the Queen's Printer for Scotland.
Br J Haematol. 2011 Aug;154(4):425-40. doi: 10.1111/j.1365-2141.2010.0...

血小板輸血の基準値

血小板輸血のトリガーとして目標となる基準の血小板数を適応ごとに示した。

血小板輸血不応状態の要因

血小板輸血不応状態を引き起こす因子には免疫性のものと非免疫性のものがある。前者で最も頻度の高いのは抗HLA抗体で、効果的な輸血を行うためにはHLA適合血小板を投与する。

輸血による副作用の予想リスク

輸血による副作用の予想発生リスクを示した1)。感染症の頻度については、日本赤十字社医薬品情報にて経年で収集された症例数とわが国の年間推定輸血施行数600万回から計算した2)。
 
参考文献：
1) Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet. 2007; 370(9585): 415-26. PMID: 17679019
2) 日本赤十字社. 輸血情報. [https://www.jrc.or.jp/mr/news/transfusion/]（2025年1月参照）

造血障害に起因した血小板減少による皮下出血

血小板数：5,000/μL＞

震盪条件下で保存されている濃厚血小板

輸血基準値と出血リスク（RCTメタ解析、森林プロット）中等度以上の出血エピソード発生イベント数の比較

出典
imgimg
1: Platelet transfusions for patients with haematological malignancies: who needs them?
著者: Estcourt LJ, Stanworth SJ, Murphy MF.
雑誌名: Br J Haematol. 2011 Aug;154(4):425-40. doi: 10.1111/j.1365-2141.2010.08483.x. Epub 2011 May 25.
Abstract/Text: The goal of platelet transfusions is to prevent severe and life-threatening bleeding in patients with thrombocytopenia. This aim needs to be balanced against the risks associated with platelet transfusions as well as the challenge of maintaining an adequate supply. This review summarizes the recent evidence regarding the clinical use of platelet transfusions in haematology patients, concentrating on the topics that still continue to provoke debate. These include the optimal dose for platelet transfusions and the relative safety of a 'therapeutic only' platelet transfusion strategy compared to the use of prophylactic platelet transfusions. The type of platelet product has been the subject of two recent systematic reviews. The results of these reviews will be discussed as well as their implications for current practice.

Published with the permission of the Controller of HMSO and the Queen's Printer for Scotland.
Br J Haematol. 2011 Aug;154(4):425-40. doi: 10.1111/j.1365-2141.2010.0...

血小板輸血の基準値

血小板輸血のトリガーとして目標となる基準の血小板数を適応ごとに示した。